• Handling mammalian and primary human immune cells-isolation, culture and characterization.• Discovery and development of the Next generation PRIAMB and PraedicareDx Platforms using Flow cytometry, ELISA and plate-based biomarker assays.• Development of translational clinical studies to validate Multi-color flow cytometry-based assay utility in predictive diagnostics • Measuring BCL-2 complex proteins-Apoptotic Priming and Dependencies assay as a companion pharmacodynamic, prognostic and predictive diagnostic test.• Design and develop cell-based assays to characterize drug candidates using mammalian cell culture and clinical samples.• Optimization and execution of ELISA in different formats to test the functionality of various monoclonal/conjugate antibodies.

Acinar cell-endothelial cell crosstalk in pancreatitis; Characterization of a new humanizedTransgenic mouse model.

Project: Investigated the mechanism of Cisplatin Resistance of Muscle Invasive Bladder Cancer.• Developed predictive biomarkers of bladder cancer that identify patients who are poor chemotherapy candidates.• Identified potential mechanism for re-sensitizing nonresponsive bladder cancers to chemotherapy.• Studied the role of phosphorylated CDK2 as a potential target in the modulation of cisplatin resistance using global proteome and phosphoproteome combined with bioinformatics analysis and various cells based assays. • Examined Palmitoylation of PD-L1/FASN contributes to cisplatin resistance in Bladder cancer using Low background Acyl-Biotin Exchange (LB-ABE) assay.Project: Molecular Mechanism and Biomarkers stratification of Interstitial Cystitis (IC)• Identified and validated sensitive and noninvasive biomarkers using urine specimens stratify IC patients from healthy subjects.• Studied specific metabolites that are perturbed in urine specimens from IC patients using metabolomics techniques.